ENANTA PHARMACEUTICALS, INC Deferred Federal Income Tax Expense (Benefit)
ENANTA PHARMACEUTICALS, INC (ENTA) reported Deferred Federal Income Tax Expense (Benefit) of $0 for the 12-month period ending 2025-09-30, per its 10-K filed 2025-11-19.
Financial Statements › Expense Statement › Income Tax
us-gaap:DeferredFederalIncomeTaxExpenseBenefit · last filed 2025-11-19
- ENANTA PHARMACEUTICALS, INC deferred federal income tax expense (benefit) for fiscal 2025 was $0.00.
- ENANTA PHARMACEUTICALS, INC deferred federal income tax expense (benefit) for fiscal 2024 was $0.00.
- ENANTA PHARMACEUTICALS, INC deferred federal income tax expense (benefit) for fiscal 2023 was $0.00, a 100.00% decline from fiscal 2022.
- ENANTA PHARMACEUTICALS, INC deferred federal income tax expense (benefit) for fiscal 2022 was $16.00K, a 95.34% decline from fiscal 2021.
| Period end | Deferred Federal Income Tax Expense (Benefit) 12 month |
|---|---|
| 2025-09-30 | $0.00 10-K · filed 2025-11-19 |
| 2024-09-30 | $0.00 10-K · filed 2025-11-19 |
| 2023-09-30 | $0.00 10-K · filed 2025-11-19 |
| 2022-09-30 | $16.00K 10-K · filed 2024-11-27 |
| 2021-09-30 | $343.00K 10-K · filed 2023-11-22 |
| 2020-09-30 | $8.92M 10-K · filed 2022-11-23 |
| 2019-09-30 | -$2.43M 10-K · filed 2021-11-24 |
| 2018-09-30 | $2.25M 10-K · filed 2020-11-25 |
| 2017-09-30 | -$1.50M 10-K · filed 2019-11-27 |
| 2016-09-30 | -$2.14M 10-K · filed 2018-11-29 |
| 2015-09-30 | $7.37M 10-K · filed 2017-12-11 |
| 2014-09-30 | -$13.05M 10-K · filed 2016-12-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Emergent BioSolutions Inc. (EBS) | United States | $0.347B | -2.43 |
| Larimar Therapeutics, Inc. (LRMR) | United States | $0.344B | -1.83 |
| Vogenx, Inc. (VOGX) | United States | $0.355B | |
| Benitec Biopharma Inc. (BNTC) | United States | $0.337B | -10.08 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| Rezolute, Inc. (RZLT) | United States | $0.382B | -6.45 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |